The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MREO | -40.63% | -1.44% | -0.29% | -68% |
| S&P | +13.09% | +85.73% | +13.17% | +135% |
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 100.0% |
| Gross Margin | 14.00% | 0.0% |
| Market Cap | $327.54M | -48.2% |
| Market Cap / Employee | $9.10M | 0.0% |
| Employees | 36 | 0.0% |
| Net Income | -$6.98M | 53.9% |
| EBITDA | -$10.27M | -11.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $48.70M | -39.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | -100.0% |
| Short Term Debt | $0.40M | -93.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -58.57% | 0.0% |
| Return On Invested Capital | -1351.54% | -1.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.26M | 4.8% |
| Operating Free Cash Flow | -$7.26M | 4.8% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 7.47 | 5.73 | 7.17 | 6.05 | -31.04% |
| Price to Sales | 856.45 | 651.45 | - | ||
| Price to Tangible Book Value | 7.55 | 5.79 | 7.24 | 6.10 | -31.21% |
| Enterprise Value to EBITDA | -32.27 | -26.53 | -36.60 | -27.40 | -55.01% |
| Return on Equity | -92.0% | -75.1% | -70.0% | - | |
| Total Debt | $6.43M | $0.75M | $0.60M | $0.40M | -94.06% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
